Molecular Partners AG
MOLN | SW
Overview
Corporate Details
- ISIN(s):
- CH0256379097 (+1 more)
- LEI:
- 875500AXMLDAZ4D21744
- Country:
- Switzerland
- Address:
- Wagistrasse 14, 8952 Schlieren
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
We are pioneers: inventors and developers of an entirely new class of therapeutics. As our name indicates, collaboration is in our DNA: within our team, with our partners, and with patients and providers. We build on deep trust, individual diversity, and shared passion to reach our common goal of surmounting the toughest challenges in medicine, including the treatment of cancer and other serious diseases. Our long-term strategy leverages our in-house DARPin design and development expertise combined with the capabilities of world-class partners to deliver a broad pipeline of innovative therapeutics.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Molecular Partners AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2020-07-07 07:25 |
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
|
English | 17.3 KB | |
| 2020-04-19 23:15 |
Regulatory News Service
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
|
English | 12.0 KB |
Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Molecular Partners AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-09-09 | N/A | Executive member | Sell | None | 47,784.80 CHF |
| 2024-09-09 | N/A | Executive member | Sell | None | 13,822.40 CHF |
| 2024-04-02 | N/A | Executive member | Sell | None | 243,000.00 CHF |
| 2023-11-01 | N/A | Executive member | Buy | None | 31,760.55 CHF |
| 2022-02-15 | N/A | Executive member | Sell | None | 2,410,500.00 CHF |
| 2022-02-15 | N/A | Executive member | Sell | None | 1,607,000.00 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Vimian Group AB | Sweden | VIMIAN | |
|
Virbac | France | FR000 | |
|
Vistin Pharma | Norway | VISTN | |
|
Vivesto | Sweden | VIVE | |
|
WAKAMOTO PHARMACEUTICAL CO.,LTD. | Japan | 4512 | |
|
Xlife Sciences AG | Switzerland | XLS | |
|
Xspray Pharma | Sweden | XSPRAY | |
|
Y.B Urban Renewal - Residential Development LTD | Israel | CSURE-M | |
|
YUKI GOSEI KOGYO CO.,LTD. | Japan | 4531 | |
|
Zentiva 2 | Slovakia | SKF |